TW200602058A - Fused pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives - Google Patents

Fused pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives

Info

Publication number: TW200602058A
Authority: TW; Taiwan
Prior art keywords: pyrazolo; fused; pyrimidine; pyrimidinone derivatives; compounds
Prior art date: 2004-02-27

Application number

TW094105812A

Other languages

English (en)

Inventor

Nidhi Arora

Roland Joseph Billedeau

Nolan James Dewdney

Tobias Gabriel

David Michael Goldstein

Counde O'yang

Michael Soth

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-27

Filing date

2005-02-25

Publication date

2006-01-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34919377&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200602058(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-02-25 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2006-01-16 Publication of TW200602058A publication Critical patent/TW200602058A/zh

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

TW094105812A 2004-02-27 2005-02-25 Fused pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives TW200602058A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US54858304P	2004-02-27	2004-02-27

Publications (1)

Publication Number	Publication Date
TW200602058A true TW200602058A (en)	2006-01-16

Family

ID=34919377

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW094105812A TW200602058A (en)	2004-02-27	2005-02-25	Fused pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives

Country Status (16)

Country	Link
US (1)	US7435731B2 (zh)
EP (1)	EP1737865A1 (zh)
JP (1)	JP2007523938A (zh)
KR (1)	KR100843526B1 (zh)
CN (1)	CN1926139A (zh)
AR (1)	AR048302A1 (zh)
AU (1)	AU2005219525B2 (zh)
BR (1)	BRPI0508036A (zh)
CA (1)	CA2557575A1 (zh)
CO (1)	CO5721008A2 (zh)
IL (1)	IL177569A (zh)
NO (1)	NO20064015L (zh)
RU (1)	RU2006134020A (zh)
TW (1)	TW200602058A (zh)
WO (1)	WO2005085249A1 (zh)
ZA (1)	ZA200606921B (zh)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2553724A1 (en) *	2004-02-03	2005-08-18	Abbott Laboratories	Aminobenzoxazoles as therapeutic agents
KR100844864B1 (ko) *	2004-02-27	2008-07-09	에프. 호프만-라 로슈 아게	헤테로아릴-융합 피라졸로 유도체
WO2005117909A2 (en) *	2004-04-23	2005-12-15	Exelixis, Inc.	Kinase modulators and methods of use
CA2575430A1 (en) *	2004-08-03	2006-02-16	Merck & Co., Inc.	1,3-disubstituted heteroaryl nmda/nr2b antagonists
US9512125B2 (en)	2004-11-19	2016-12-06	The Regents Of The University Of California	Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
NZ555566A (en) *	2004-11-22	2009-12-24	Vertex Pharma	Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
GB0427604D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
EP1848719B1 (en) *	2004-12-28	2012-02-01	Exelixis, Inc.	[1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
AR057455A1 (es) *	2005-07-22	2007-12-05	Merck & Co Inc	Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
EP1919470A1 (en)	2005-08-25	2008-05-14	F.Hoffmann-La Roche Ag	FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS
BRPI0615272A2 (pt) *	2005-08-25	2009-08-04	Hoffmann La Roche	inibidores de p38 map kinase e métodos para uso dos mesmos
JP2009506007A (ja)	2005-08-25	2009-02-12	エフ．ホフマン−ラロシュアーゲー	ｐ３８ＭＡＰキナーゼ阻害剤及びその使用方法
WO2007023114A1 (en)	2005-08-25	2007-03-01	F. Hoffmann-La Roche Ag	P38 map kinase inhibitors and methods for using the same
CN101365700A (zh)	2005-11-15	2009-02-11	沃泰克斯药物股份有限公司	可用作激酶抑制剂的氮杂吲唑
JP2009529047A (ja) *	2006-03-07	2009-08-13	アレイバイオファーマ、インコーポレイテッド	ヘテロ二環系ピラゾール化合物およびその使用
EP2557080A1 (en)	2006-04-04	2013-02-13	The Regents of The University of California	Method for identifying pI3-kinase antagonists
US20090192164A1 (en) *	2006-06-28	2009-07-30	Aska Pharmaceutical Co., Ltd.	Treating agent of inflammatory bowel disease
TW200831085A (en) *	2006-12-13	2008-08-01	Merck & Co Inc	Non-nucleoside reverse transcriptase inhibitors
JP2010513370A (ja) *	2006-12-19	2010-04-30	エフ．ホフマン−ラロシュアーゲー	ピラゾロ［３，４−ｄ］ピリミジンｐ３８ＭＡＰキナーゼインヒビター
EP2123654A4 (en)	2006-12-28	2011-05-11	Taisho Pharmaceutical Co Ltd	pyrazolopyrimidine compound
JP4588791B2 (ja)	2007-02-16	2010-12-01	あすか製薬株式会社	微粒子油性懸濁液を含む医薬組成物
WO2008104473A2 (en) *	2007-02-28	2008-09-04	F. Hoffmann-La Roche Ag	Pyrazolopyriidine derivatives and their use as kinase inhibitors
AU2008248296B2 (en) *	2007-05-07	2011-12-01	Amgen Inc.	Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators, process for their preparation, and their pharmaceutical use
WO2009046448A1 (en)	2007-10-04	2009-04-09	Intellikine, Inc.	Chemical entities and therapeutic uses thereof
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007418A (es) *	2008-01-04	2010-11-12	Intellikine Inc	Ciertas entidades quimicas, composiciones y metodos.
WO2009114874A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
WO2009117156A1 (en) *	2008-03-21	2009-09-24	Amgen Inc.	Pyrazolo-pyrazinone compounds and methods of use thereof
JP5788316B2 (ja)	2008-07-08	2015-09-30	インテリカイン，エルエルシー	キナーゼインヒビターおよび使用方法
WO2010006072A2 (en)	2008-07-08	2010-01-14	The Regents Of The University Of California	Mtor modulators and uses thereof
US8220787B2 (en) *	2008-09-19	2012-07-17	Panasonic Corporation	Part mounting device
JP5731978B2 (ja)	2008-09-26	2015-06-10	インテリカイン，エルエルシー	複素環キナーゼ阻害剤
WO2010045542A2 (en)	2008-10-16	2010-04-22	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
AU2010232727A1 (en) *	2009-03-31	2011-10-20	Arqule, Inc.	Substituted heterocyclic compounds
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
CN105078978A (zh)	2009-08-17	2015-11-25	因特利凯公司	杂环化合物及其用途
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
JP2013526542A (ja)	2010-05-12	2013-06-24	アッヴィ・インコーポレイテッド	キナーゼのインダゾール阻害薬
US8604032B2 (en)	2010-05-21	2013-12-10	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
EP2637669A4 (en)	2010-11-10	2014-04-02	Infinity Pharmaceuticals Inc	Heterocyclic compounds and their use
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN103648499B (zh)	2011-01-10	2017-02-15	无限药品股份有限公司	用于制备异喹啉酮的方法及异喹啉酮的固体形式
US8362023B2 (en)	2011-01-19	2013-01-29	Hoffmann-La Roche Inc.	Pyrazolo pyrimidines
AR085397A1 (es)	2011-02-23	2013-09-25	Intellikine Inc	Combinacion de inhibidores de quinasa y sus usos
CN103930422A (zh)	2011-07-19	2014-07-16	无限药品股份有限公司	杂环化合物及其用途
AU2012284091B2 (en)	2011-07-19	2015-11-12	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
CN103998442B (zh)	2011-08-29	2016-09-14	无限药品股份有限公司	杂环化合物及其用途
JP6342805B2 (ja)	2011-09-02	2018-06-13	ザリージェンツオブザユニバーシティオブカリフォルニア	置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
NZ628084A (en)	2012-03-16	2016-09-30	Axikin Pharmaceuticals Inc	3,5-diaminopyrazole kinase inhibitors
KR101379808B1 (ko)	2012-04-03	2014-04-24	울산대학교 산학협력단	산화질소 생성 억제용 피라졸로피리미딘 유도체 화합물
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3822273B1 (en)	2012-06-13	2024-04-10	Incyte Holdings Corporation	Substituted tricyclic compounds as fgfr inhibitors
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
RU2015115631A (ru)	2012-09-26	2016-11-20	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Модулирование ire1
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN105209042B (zh)	2013-03-22	2019-03-08	米伦纽姆医药公司	催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
SG10201708520YA (en)	2013-04-19	2017-12-28	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
MX2021012208A (es)	2013-10-04	2023-01-19	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos y usos de los mismos.
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CA2943075C (en)	2014-03-19	2023-02-28	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
CN105622613B (zh) *	2014-11-14	2019-03-12	安礼特（上海）医药科技有限公司	一种合成伊鲁替尼的方法
ES2805528T3 (es)	2014-12-23	2021-02-12	Sma Therapeutics Inc	Inhibidores de 3,5-diaminopirazol quinasa
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MX2017010673A (es)	2015-02-20	2018-03-21	Incyte Corp	Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
US10160761B2 (en)	2015-09-14	2018-12-25	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP7054681B2 (ja)	2016-06-24	2022-04-14	インフィニティーファーマシューティカルズ，インコーポレイテッド	組合せ療法
TW201811799A (zh)	2016-09-09	2018-04-01	美商英塞特公司	吡唑并嘧啶化合物及其用途
WO2018049191A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
IL292977A (en)	2016-09-09	2022-07-01	Incyte Corp	Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
WO2018049214A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180228786A1 (en)	2017-02-15	2018-08-16	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019051199A1 (en)	2017-09-08	2019-03-14	Incyte Corporation	6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
MD3755703T2 (ro)	2018-02-20	2022-10-31	Incyte Corp	Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului
US10752635B2 (en)	2018-02-20	2020-08-25	Incyte Corporation	Indazole compounds and uses thereof
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
CN112566912A (zh)	2018-05-04	2021-03-26	因赛特公司	Fgfr抑制剂的盐
CN112867716A (zh)	2018-05-04	2021-05-28	因赛特公司	Fgfr抑制剂的固体形式和其制备方法
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
MA53726A (fr)	2018-09-25	2022-05-11	Incyte Corp	Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3147918A1 (en)	2019-08-06	2021-02-11	Incyte Corporation	Solid forms of an hpk1 inhibitor
AU2020366006A1 (en)	2019-10-14	2022-04-21	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
CN114667282A (zh) *	2019-10-22	2022-06-24	昊运股份有限公司	嘧啶酰胺化合物及治疗癌症的方法
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko)	2019-12-04	2022-09-29	인사이트 코포레이션	Fgfr 억제제의 유도체
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BG17006A3 (zh) *	1969-10-28	1973-04-25
US3821382A (en) *	1969-10-28	1974-06-28	Ciba Geigy Corp	5-nitrofuryl derivatives as antibacterial agents
BE758050A (fr) *	1969-10-28	1971-04-27	Geigy Ag J R	Derives 5-nitro-furyliques et medicaments contenant de tels composes
US4020072A (en)	1976-05-04	1977-04-26	E. R. Squibb & Sons, Inc.	5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
US4260505A (en) *	1978-10-25	1981-04-07	Olin Corporation	Tris-(polyalkoxyalkylated) isocyanurate compounds and their use as functional fluids
IT1154024B (it) *	1982-09-22	1987-01-21	Lepetit Spa	Derivati pridinici e procedimento per la loro produzione
KR100429950B1 (ko)	1995-07-31	2004-06-16	시오노기세이야쿠가부시키가이샤	포스포리파제에이2저해활성을갖는피롤리딘유도체
EA002113B1 (ru)	1996-09-04	2001-12-24	Пфайзер Инк.	Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
JP2001521926A (ja)	1997-11-04	2001-11-13	ファイザー・プロダクツ・インク	治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
WO2000027627A1 (en)	1998-11-12	2000-05-18	Eli Lilly And Company	Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
DE1140938T1 (de) *	1999-01-11	2003-01-09	Princeton University Princeton	Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
DK1212327T3 (da) *	1999-09-17	2003-12-15	Abbott Gmbh & Co Kg	Pyrazolopyrimidiner som terapeutiske midler
EP1148054B1 (en)	2000-04-21	2005-11-23	Pfizer Products Inc.	Thyroid receptor ligands
AU2001264313A1 (en)	2000-06-20	2002-01-02	Japan Tobacco Inc.	Pyrazolopyridine compounds and use thereof as drugs
DE10046029A1 (de)	2000-09-18	2002-03-28	Bayer Ag	Indazole
CN1281605C (zh)	2000-12-22	2006-10-25	惠氏公司	作为5－羟色胺－6配基的杂环基－吲唑或氮杂吲唑化合物
TW593278B (en)	2001-01-23	2004-06-21	Wyeth Corp	1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US20030114467A1 (en)	2001-06-21	2003-06-19	Shakespeare William C.	Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
US20040235867A1 (en)	2001-07-24	2004-11-25	Bilodeau Mark T.	Tyrosine kinase inhibitors
DE60228103D1 (de) *	2001-10-02	2008-09-18	Smithkline Beecham Corp	Chemische verbindungen
JP2005519915A (ja)	2002-01-18	2005-07-07	セレテック・リミテッド・ライアビリティ・カンパニー	Ｅｄｇ受容体に関連する症状の処置方法
TW200302722A (en)	2002-02-13	2003-08-16	Astrazeneca Ab	Therapeutic agents
JP4187657B2 (ja)	2002-03-07	2008-11-26	エフ．ホフマン−ラロシュアーゲー	ｐ３８キナーゼインヒビターとしての二環式ピリジン及びピリミジン
TW200400034A (en) *	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
CA2492112A1 (en) *	2002-08-06	2004-02-19	F. Hoffmann-La Roche Ag	6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
US7135575B2 (en)	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
KR100844864B1 (ko) *	2004-02-27	2008-07-09	에프. 호프만-라 로슈 아게	헤테로아릴-융합 피라졸로 유도체
US7405220B2 (en) *	2004-06-09	2008-07-29	Hoffmann-La Roche Inc.	Pyrazolopyrimidines

2005
- 2005-02-24 AU AU2005219525A patent/AU2005219525B2/en not_active Expired - Fee Related
- 2005-02-24 KR KR1020067017111A patent/KR100843526B1/ko not_active IP Right Cessation
- 2005-02-24 CA CA002557575A patent/CA2557575A1/en not_active Abandoned
- 2005-02-24 JP JP2007500149A patent/JP2007523938A/ja active Pending
- 2005-02-24 CN CNA2005800063442A patent/CN1926139A/zh active Pending
- 2005-02-24 BR BRPI0508036-3A patent/BRPI0508036A/pt not_active IP Right Cessation
- 2005-02-24 RU RU2006134020/04A patent/RU2006134020A/ru not_active Application Discontinuation
- 2005-02-24 EP EP05707608A patent/EP1737865A1/en not_active Withdrawn
- 2005-02-24 WO PCT/EP2005/001936 patent/WO2005085249A1/en active Application Filing
- 2005-02-25 TW TW094105812A patent/TW200602058A/zh unknown
- 2005-02-25 US US11/067,336 patent/US7435731B2/en not_active Expired - Fee Related
- 2005-02-25 AR ARP050100697A patent/AR048302A1/es not_active Application Discontinuation
2006
- 2006-08-17 IL IL177569A patent/IL177569A/en not_active IP Right Cessation
- 2006-08-18 ZA ZA200606921A patent/ZA200606921B/xx unknown
- 2006-08-30 CO CO06086249A patent/CO5721008A2/es not_active Application Discontinuation
- 2006-09-06 NO NO20064015A patent/NO20064015L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1737865A1 (en)	2007-01-03
US20050197340A1 (en)	2005-09-08
CN1926139A (zh)	2007-03-07
IL177569A0 (en)	2006-12-10
RU2006134020A (ru)	2008-04-10
ZA200606921B (en)	2008-08-27
KR100843526B1 (ko)	2008-07-03
BRPI0508036A (pt)	2007-07-17
CA2557575A1 (en)	2005-09-15
WO2005085249A1 (en)	2005-09-15
NO20064015L (no)	2006-11-23
US7435731B2 (en)	2008-10-14
CO5721008A2 (es)	2007-01-31
IL177569A (en)	2012-08-30
JP2007523938A (ja)	2007-08-23
AU2005219525A1 (en)	2005-09-15
AU2005219525B2 (en)	2011-08-18
KR20060114019A (ko)	2006-11-03
AR048302A1 (es)	2006-04-19

Publication	Publication Date	Title
TW200602058A (en)	2006-01-16	Fused pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives
UA95230C2 (ru)	2011-07-25	ЗАМЕЩЕННЫЕ ТЕТРАГИДРОПИРИМИДО[4,5-d]ПИРИМИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ, И ИХ ПРИМЕНЕНИЕ
MXPA06000716A (es)	2006-03-30	Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
MXPA05005199A (es)	2005-08-18	Compuestos de pirimidina.
TW200740815A (en)	2007-11-01	P38 MAP kinase inhibitors and methods for using the same
WO2006065590A3 (en)	2006-09-21	Pyridine and pyrimidine antiviral compositions
MX2007001289A (es)	2007-06-25	Piridinas condensadas como inhibidores de cinasa.
MX337817B (es)	2011-11-04	Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
TW200744604A (en)	2007-12-16	P38 MAP kinase inhibitors and methods for using the same
RS20050810A (en)	2007-08-03	5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
MX2009004807A (es)	2009-06-15	Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
RS20060264A (en)	2008-06-05	Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs
MXPA05007503A (es)	2005-09-21	Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
IN2014DN06567A (zh)	2015-07-10
TW200608977A (en)	2006-03-16	Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
TW200740816A (en)	2007-11-01	P38 MAP kinase inhibitors and methods for using the same
HK1091200A1 (en)	2007-01-12	Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists
MY145281A (en)	2012-01-13	Novel compounds
NO20080418L (no)	2008-03-28	Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme
WO2004092144A3 (en)	2005-03-24	Quinazoline compounds useful as p38 kinase inhibitors
ATE370952T1 (de)	2007-09-15	Neue verbindungen
WO2005097755A3 (de)	2006-03-09	Imidazolderivate als hemmer von tyrosinkinase
TW200738721A (en)	2007-10-16	7-Amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and their use for controlling harmful fungi
MXPA05010975A (es)	2005-11-28	Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
MXPA04005151A (es)	2004-08-11	Compuestos terapeuticos.